Clinical trial started at PGIMER Chandigarh to position Sepsivac as drug for COVID-19 treatment: CSIR-IIIM Director

CSIR-IIIM Director and coordinator of trial programme for use of Sepsivac in COVID-19 treatment, Dr. Ram Vishwakarma said that Clinical trial has begun at PGIMER Chandigarh to position immunomodulator Sepsivac as a drug. "We're doing another trial on asymptomatic COVID-19 patients. It'll be given to them as vaccine," he added.